Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C

Bibliography

• MohdHanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57(4):1333-42
   PubMed Web of Science ®Google Scholar
• Pearlman BL. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis 2012;12(9):717-28
   PubMed Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, Seef LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49(4):1335-74
   PubMed Web of Science ®Google Scholar
• Powley MW. Department of health and human services public health service food and drug administration center for drug evaluation and research. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201917Orig1s000ODMemo.pdf
   Google Scholar
• Antiviral Drugs Advisory Committee. Telaprevir briefing document. Available from: http://www.fda.gov/downloads/Advisory/Committees/Committees/MeetingMa erials/Drugs/AntiviralDrugsAdvisory-Committee/UCM252562.pdf [Last accessed 28 April 2011]
   Google Scholar
• Perni RB, Almquist SJ, Byrn RA, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006;50(3):899-909
   PubMed Web of Science ®Google Scholar
• Chakilam A, Chavan A, Smith G, et al. Telaprevir binding to isolated human plasma proteins and protein binding displacement interactions between telaprevir and warfarin. 6th international workshop on clinical pharmacology of hepatitis therapy [online]. 2011.Available from: http://regist2.virology-education. com/2011/6HEPPK/docs/14_Garg.pdf [Last accessed 29 October 2012]
   Google Scholar
• Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131(4):997-1002
   PubMed Web of Science ®Google Scholar
• Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008;49(2):163-9
   PubMed Web of Science ®Google Scholar
• Karino T, Ozeki I, Hige S, et al. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. J Viral Hepat 2014;21(5):341-7
   PubMed Web of Science ®Google Scholar
• Bodeau S, Nguyen-Khac E, Solas C, et al. Patients treated with first-generation HCV protease inhibitors exhibits high ribavirin concentrations. J Clin Pharmacol 2015;55(5):517-24
   PubMed Web of Science ®Google Scholar
• Cotte L, Barrail-Tran A, Vincent C, et al. Telaprevir enhances ribavirin-induced anaemia through renal function impairment. Antivir Ther 2014. [Epub ahead of print]
   Google Scholar
• Van Heeswijk R, Boogaerts G, De Paepe E, et al. The effect of different types of food on the bioavailability of the investigational HCV protease inhibitor telaprevir. Rev Antiviral Ther Infect Dis 2011;6:21
   Google Scholar
• Seyam MS, Freshwater DA, O’Donnell K, et al. Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C. J Viral Hepat 2005;12(5):531-5
   PubMed Web of Science ®Google Scholar
• Furusyo N, Ogawa E, Murata M, et al. Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. J Antimicrob Chemother 2014;69(2):483-90
   PubMed Web of Science ®Google Scholar
• Talal AH, Dimova RB, Zhang EZ, et al. Telaprevir-based treatment effects on hepatitis C virus in liver and blood. Hepatology 2014;60(6):1826-37
   PubMed Web of Science ®Google Scholar
• Di Marco S, Rizzi M, Volpari C, et al. Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes. J Biol Chem 2000;275(10):7152-7
   PubMed Web of Science ®Google Scholar
• Garg V, Chandorkar G, Yang Y, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol 2013;75(2):431-9
   PubMed Web of Science ®Google Scholar
• Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006;6(1):3-16
   PubMedGoogle Scholar
• Kunze A, Huwyler J, Camenisch G, et al. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol 2012;84(8):1096-102
   PubMed Web of Science ®Google Scholar
• Fujita Y, Noguchi K, Suzuki T, et al. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein. BMC Res Notes 2013;6:445
   PubMedGoogle Scholar
• Furihata T, Matsumoto S, Fu Z, et al. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother 2014;58(8):4555-64
   PubMed Web of Science ®Google Scholar
• Kiang TK, Wilby KJ, Ensom MH. Telaprevir: Clinical Pharmacokinetics, Pharmacodynamics, and Drug–Drug Interactions. Clin Pharmacokinet 2013;52:487-510
   PubMed Web of Science ®Google Scholar
• Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)- NCT01514890. J Hepatol 2013;59(3):434-41
   PubMed Web of Science ®Google Scholar
• Verna EC, Shetty K, Lukose T, et al. High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy. Liver Int 2015;35(2):510-17
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Pawlotsky JM, Afdhal NH, et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat 2012;19(Suppl 2):1-26
   PubMed Web of Science ®Google Scholar
• Adiwijaya B, Chandorkar G, Van Heeswijk R, et al. Effect of mild and moderate hepatic impairment on telaprevir pharmacokinetics. Rev Antiviral Ther Infect Dis 2011;6:3
   Google Scholar
• Loustaud-Ratti V, Rousseau A, Carrier P, et al. eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance? Liver Int 2015;35(1):71-8
   PubMed Web of Science ®Google Scholar
• Morihara D, Watanabe H, Takata K, et al. Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate. Eur J Gastroenterol Hepatol 2015;27(1):55-64
   PubMed Web of Science ®Google Scholar
• Mauss S, Hueppe D, Alshuth U. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology 2014;59(1):46-8
   PubMed Web of Science ®Google Scholar
• Fukuda K, Imai Y, Hiramatsu N, et al. Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C. Hepatol Res 2014;44(12):1165-71
   PubMed Web of Science ®Google Scholar
• Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013;19(7):837-49
   PubMed Web of Science ®Google Scholar
• Hoffman B, Liu Q. Hepatitis C viral protein translation: mechanisms and implications in developing antivirals. Liver Int 2011;31(10):1449-67
   PubMed Web of Science ®Google Scholar
• Morikawa K, Lange CM, Gouttenoire J, et al. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus. J Viral Hepat 2011;18(5):305-15
   PubMed Web of Science ®Google Scholar
• Ploss A, Dubuisson J. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets. Gut 2012;61(Suppl 1):i25-35
   PubMed Web of Science ®Google Scholar
• Yao N, Reichert P, Taremi SS, et al. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 1999;7(11):1353-63
   PubMed Web of Science ®Google Scholar
• Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996;87(2):343-55
   PubMed Web of Science ®Google Scholar
• Kwong AD, Kauffman RS, Hurter P, et al. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol 2011;29(11):993-1003
   PubMed Web of Science ®Google Scholar
• Chen SH, Tan SL. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection. Curr Med Chem 2005;12(20):2317-42
   PubMed Web of Science ®Google Scholar
• Lin K, Kwong AD, Lin C. Combination of a hepatitis C virus NS3–NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother 2004;48(12):4784-92
   PubMed Web of Science ®Google Scholar
• Kalkeri G, Almquist KS. Expression of HCV protease in mouse liver results in liver injury which can be inhibited by VX-950. Hepatology 2004;40(Suppl 4):281A
   Web of Science ®Google Scholar
• Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007;46(3):631-9
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360(18):1827-38
   PubMed Web of Science ®Google Scholar
• Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360(18):1839-50
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362(14):1292-303
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364(25):2405-16
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364(25):2417-28
   PubMed Web of Science ®Google Scholar
• Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365(11):1014-24
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013;159(2):86-96
   PubMed Web of Science ®Google Scholar
• Buti M, Agarwal K, Horsmans Y, et al. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. Gastroenterology 2014;146(3):744-53
   PubMed Web of Science ®Google Scholar
• Adiwijaya BS, Herrmann E, Hare B, et al. A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput Biol 2010;6(4):e1000745
   PubMedGoogle Scholar
• Adiwijaya BS, Kieffer TL, Henshaw J, et al. A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection. PLoS Comput Biol 2012;8(1):e1002339
   PubMedGoogle Scholar
• Foster GR, Hézode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011;141(3):881-9
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Moussalli J, Ratziu V, et al. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial. J Infect Dis 2013;208(6):1000-7
   PubMed Web of Science ®Google Scholar
• Recommendations for Testing. Managing, and treating hepatitis c of the american association for the study of liver diseases (AASLD) and the infectious diseases society of america (IDSA). Available from: http://www.hcvguidelines.org [Last accessed 6th April 2015]
   Google Scholar
• European Association for the Study of the Liver (EASL). Recommendations on treatment of hepatitis C. 2014. Available from: http://www.easl.eu/_newsroom/latest-news/easl-recommendations-on-treatment-of-hepatitis-c-2014 [Last accessed 6 April 2015]
   Google Scholar
• Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370(21):1983-92
   PubMed Web of Science ®Google Scholar
• Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with Daclatasvir plus Sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61(4):1127-35
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and Sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370(20):1879-88
   PubMed Web of Science ®Google Scholar
• Cachay ER, Wyles DL, Torriani FJ, et al. High incidence of serious adverse events in HIV-infected patients treated with telaprevir-based hepatitis C virus treatment regimen. AIDS 2013;27(18):2893-7
   PubMed Web of Science ®Google Scholar
• Milazzo L, Cattaneo D, Calvi E, et al. Pharmacokinetic interactions between telaprevir and antiretroviral drugs in HIV/HCV-coinfected patients with advanced liver fibrosis and prior HCV non-responders. Int J Antimicrob Agents 2015. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Reddy KR, Zeuzem S, Zoulim F, et al. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect Dis 2015;15(1):27-35
   PubMed Web of Science ®Google Scholar
• Feld JJ, Kowdley KV, Coakley et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370(17):1594-603
   PubMed Web of Science ®Google Scholar